<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120687">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531673</url>
  </required_header>
  <id_info>
    <org_study_id>VX11-661-101</org_study_id>
    <secondary_id>2011-003821-93</secondary_id>
    <nct_id>NCT01531673</nct_id>
  </id_info>
  <brief_title>Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and
      pharmacodynamics (PD) effects of VX-661 alone and when coadministered with ivacaftor in
      subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, multicenter, double-blinded, placebo-controlled, study of VX
      661 monotherapy, and VX 661/ivacaftor co-therapy in subjects with CF who are homozygous or
      heterozygous for the F508del CFTR mutation.

      This study will be separated into seven groups: Group 1-7, respectively. Approximately 180
      subjects will be randomized in a ratio of 4:1; active drug to matching placebo in each
      group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of active drug vs placebo</measure>
    <time_frame>Through Day 56</time_frame>
    <description>Measured by incidence of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of active drug vs placebo</measure>
    <time_frame>Through Day 56</time_frame>
    <description>Measured by clinical laboratory values (serum chemistry, hematology, coagulation studies, and urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of active drug vs placebo</measure>
    <time_frame>Through Day 56</time_frame>
    <description>Measured by 12-lead ECG outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of active drug vs placebo</measure>
    <time_frame>Through Day 56</time_frame>
    <description>Measured by vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in sweat chloride</measure>
    <time_frame>From baseline across all visits through Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in sweat chloride</measure>
    <time_frame>From baseline to each visit up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent predicted forced expiratory volume in 1 second</measure>
    <time_frame>From baseline to each visit and from baseline through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced expiratory volume in 1 second</measure>
    <time_frame>From baseline to each visit and from baseline through Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score</measure>
    <time_frame>From baseline to each visit up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters [Cmax, Cmin, Cavg, area under the concentration versus time curve(AUC), tmax] of VX-661, ivacaftor, and their respective metabolites in plasma when VX-661 is administered alone and when the 2 drugs are administered together</measure>
    <time_frame>Through 56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>22</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 10 mg VX-661 monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 30 mg VX-661 monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 10 mg VX-661 once daily and 150 mg ivacaftor twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 100 mg VX-661 monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 30 mg VX-661 once daily and ivacaftor 150mg twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 100 mg VX-661 once daily and ivacaftor 150mg twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 150 mg VX-661 monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 150 mg VX-661 once daily and ivacaftor 150 mg twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 100 mg VX-661 once daily and ivacaftor 50 mg twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d homozygous subjects to receive 50 mg VX-661 twice daily and ivacaftor 150 mg twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F508d/G551D subjects to receive 100 mg VX-661 once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo once daily and ivacaftor-placebo twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo once daily and ivacaftor-placebo twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo once daily and ivacaftor-placebo twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5a - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo monotherapy once daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5b - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo once daily and ivacaftor-placebo twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6a - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo once daily and ivacaftor-placebo twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6d - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d homozygous subjects to receive VX-661-placebo twice daily and ivacaftor-placebo twice daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>F508d/G551D subjects to receive VX-661-placebo once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-661</intervention_name>
    <description>Tablet, taken once daily (qd)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 3a</arm_group_label>
    <arm_group_label>Group 3b</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5a</arm_group_label>
    <arm_group_label>Group 5b</arm_group_label>
    <arm_group_label>Group 6a</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivacaftor</intervention_name>
    <description>Tablet, taken every 12 hours (q12h)</description>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 3b</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5b</arm_group_label>
    <arm_group_label>Group 6a</arm_group_label>
    <arm_group_label>Group 6d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-661 placebo</intervention_name>
    <description>Tablet, taken once daily (qd)</description>
    <arm_group_label>Group 1 - Placebo</arm_group_label>
    <arm_group_label>Group 2a - Placebo</arm_group_label>
    <arm_group_label>Group 2b - Placebo</arm_group_label>
    <arm_group_label>Group 3a - Placebo</arm_group_label>
    <arm_group_label>Group 3b - Placebo</arm_group_label>
    <arm_group_label>Group 4 - Placebo</arm_group_label>
    <arm_group_label>Group 5a - Placebo</arm_group_label>
    <arm_group_label>Group 5b - Placebo</arm_group_label>
    <arm_group_label>Group 6a - Placebo</arm_group_label>
    <arm_group_label>Group 7 - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivacaftor placebo</intervention_name>
    <description>Tablet, taken every 12 hours (q12h)</description>
    <arm_group_label>Group 2b - Placebo</arm_group_label>
    <arm_group_label>Group 3b - Placebo</arm_group_label>
    <arm_group_label>Group 4 - Placebo</arm_group_label>
    <arm_group_label>Group 5b - Placebo</arm_group_label>
    <arm_group_label>Group 6a - Placebo</arm_group_label>
    <arm_group_label>Group 6d - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-661</intervention_name>
    <description>Tablet, taken every 12 hours (q12h)</description>
    <arm_group_label>Group 6d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-661 placebo</intervention_name>
    <description>Tablet, taken every 12 hours (q12h)</description>
    <arm_group_label>Group 6d - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female with confirmed diagnosis of CF

          -  Must have the F508del-CFTR gene mutation in both alleles (Groups 1, 2, 3, 4, 5, 6).
             Group 7 subjects must have the F508del-CFTR mutation on 1 allele, and gating mutation
             G551D on the second allele and have been on their physician prescribed 150 mg
             KalydecoTM q12h (commercially available ivacaftor) for at least 28 days at the
             Screening Visit.

          -  Forced expiratory volume in 1 second(FEV1) 40% to 90% (inclusive) of predicted normal
             for age, gender, and height (Knudson standards) at screening

          -  Weight &gt;40 kg and BMI &gt;18.5

          -  Subjects of child-bearing potential and who are sexually active must meet the
             contraception requirements.

        Exclusion Criteria:

          -  History of any illness that, in the opinion of the investigator, might confound the
             results of the study or pose an additional risk in administering study drug to the
             subject.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 4 weeks before Study Day
             1.

          -  History of solid organ or hematological transplantation

          -  Participation in a clinical study involving administration of either an
             investigational or a marketed drug within 30 days or 5 terminal half-lives (whichever
             is longer) before screening

          -  History of alcohol, medication, or illicit drug abuse within 1 year prior to
             screening

          -  Pregnant, breast-feeding, or not willing to follow contraception requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Donaldson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Southhampton</city>
        <state>Hampshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <state>Vale of Glamorgen</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 5, 2015</lastchanged_date>
  <firstreceived_date>February 1, 2012</firstreceived_date>
  <firstreceived_results_disposition_date>May 5, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
